Omabit Raises $2M Seed Led by Bright Ventures for AI-Driven Genomic Analysis

Omabit Secures $2M Seed Round

Omabit, a Palo Alto-based AI platform for life science R&D, has raised a $2 million seed round led by Bright Ventures. The funding lands as the company positions itself at the intersection of genomic analysis and large-scale scientific literature review, a combination it says can compress research timelines dramatically.

What Omabit Does

Omabit builds an AI platform that lets pharma and biotech teams run genomic analysis in plain English. Researchers point the system at clinical trial data, sequencing results or variant calls, and it runs the analysis, checks each finding against more than 200,000 published papers, and returns a write-up with the code behind every figure.

The company says this approach cuts analysis cycles from roughly three months to about one day. Its users span preclinical research, clinical development and diagnostics through Phase 2 trials.

Company Background

Omabit was formerly known as SeqGPT. The startup is based in Palo Alto, California, and is part of the StartX Summer 2026 cohort. It was founded by Elena Cassidy, Jesse Eaton and Jay Sarkar.

Round Details

• Round type: Seed
• Amount: $2,000,000 USD
• Lead investor: Bright Ventures
• Announced: October 26, 2026

Bright Ventures led the round as the sole named investor in the filing.

Why It Matters for Acquisition Watchers

Omabit sits in a category where the value proposition is measured in time saved on high-cost research workflows. Genomic analysis for clinical trials and diagnostics is typically labor-intensive, requiring specialized bioinformatics staff to move from raw sequencing data to interpretable findings. A platform that automates both the analysis and the literature cross-check — while returning reproducible code behind each figure — addresses two persistent bottlenecks: turnaround time and auditability.

The company's stated coverage through Phase 2 trials suggests early traction in clinical development settings, a segment where buyers tend to be large pharma organizations with long sales cycles but substantial contract values. For strategic acquirers in life science tools, clinical research software or AI-enabled drug discovery, Omabit represents an early-stage asset with a defined technical wedge: natural-language interfaces layered over genomic pipelines with citation-backed outputs.

The seed round is modest, which is typical at this stage. The key signals to track going forward will be customer expansion beyond the current preclinical-to-Phase 2 footprint, evidence of repeat usage among named pharma or biotech teams, and whether the company builds proprietary data advantages from its literature-checking layer.

The Team

Omabit's founding team consists of Elena Cassidy, Jesse Eaton and Jay Sarkar. The company's participation in the StartX Summer 2026 cohort places it within a well-known early-stage founder network, which can be relevant for both follow-on fundraising and introductions to enterprise buyers.

Outlook

With $2 million in seed capital and a lead investor in place, Omabit's next milestones will likely center on deepening its platform's coverage and converting pilot users into durable contracts. For acquirers monitoring the AI-for-life-sciences space, Omabit is a name worth watching as it moves from seed stage toward proof of commercial scale.